DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA
AssigneeBoard of Regents, The University of Texas System
InventorsJing Zou, Xuping Xie, Pei-Yong Shi
Life of this patent
Estimating the term…
Abstract
The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.
Claims6
An immunogenic composition comprising a DNA plasmid comprising from 5′ to 3′ (a) a promoter segment active in a mammalian cell, (b) a cDNA of a live-attenuated Zika virus (ZIKV) genome comprising (i) a 5′ untranslated region, (ii) a coding region for the live-attenuated Zika virus (ZIKV), and (iii) a 3′ untranslated region, (c) a hepatitis delta virus ribzyme (HDVr) segment, and (d) a polyadenylation signal.
Dependencies are inferred from the claim text.